In April, Gundy’s child, who is on private insurance, began getting the drug Spinraza, which costs $750,000 for the initial year of treatment. Chaffin’s child — a Medicaid enrollee — was not receiving the drug, as his state regulators debated whether to offer it to children like him who use ventilators to breathe

Quick Read

With a flagship treatment that helps fewer than 11,000 people, how is Alexion making so much money?

Quick Read

The latest flashpoint in the ongoing debate over high drug prices is Emflaza, an $89,000-a-year drug that treats Duchenne muscular dystrophy

Quick Read

In Sierra Leone alone, a country of just over six million people, the Ebola epidemic has orphaned more than 12,000 children who have lost one or both family members, according to Street Child, a British charity

Quick Read